A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis

The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo. The protocol describes a randomized, double-blind, multi-dose, placebo-controlled, parallel study of a 7 day treatment.

Study Overview

• Status: Completed
• Conditions: Atrophic Vaginitis
• Intervention / Treatment: Drug: Estradiol Vaginal Cream, 0.01%; Drug: Estrace® 0.01% cream; Drug: Placebo Vaginal Cream

• Study Type: Interventional
• Enrollment (Actual): 366
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Tucson, Arizona, United States, 85712
      • ARA-Arizona Research Associates
  • California
    • Los Angeles, California, United States, 90036
      • Axis Clinical Trials
    • Sacramento, California, United States, 95821
      • Northern CA Research
    • San Diego, California, United States, 92123
      • Women's Health Care Research Corp.
    • San Diego, California, United States, 92108
      • MCCR
  • Colorado
    • Colorado Springs, Colorado, United States, 80910
      • MCB Clinical Research Centers
    • Denver, Colorado, United States, 80220
      • Horizons Clinical Research Center, LLC
    • Denver, Colorado, United States, 80209
      • Downtown Women's Health Care
  • Florida
    • Coral Springs, Florida, United States, 33065
      • Sunrise Medical Research
    • Jupiter, Florida, United States, 33458
      • Health Awareness, Inc.
    • Lakeland, Florida, United States, 33805
      • Meridien Research
    • Leesburg, Florida, United States, 34748
      • OB-GYN Associates of Mid Florida
    • Miami, Florida, United States, 33136
      • SouthCoast Research Center
    • Miami Lakes, Florida, United States, 33014
      • Veritas Research, Corp.
    • Saint Petersburg, Florida, United States, 33709
      • Meridien Research
    • Sarasota, Florida, United States, 34239
      • Physician Care Clinical Research LLC
    • Tamarac, Florida, United States, 33351
      • Sunrise Medical Research
    • West Palm Beach, Florida, United States, 33409
      • Comprehensive Clinical Trials, Llc
  • Georgia
    • Atlanta, Georgia, United States, 30312
      • Georgia Center For Women
  • New Jersey
    • Lawrenceville, New Jersey, United States, 08690
      • Lawrence OB/GYN Clinical Research, LLC
    • Plainsboro, New Jersey, United States, 08536
      • Women's Health Research Center/The Center for Women's Health & Wellness, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Capable of providing informed consent.
2. Age: 40-70 years old.
3. Sex: Female
4. Postmenopausal defined as at least 12 months of spontaneous amenorrhea or at least 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or at least 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
5. Weight: At least 48 kg with all subjects having a Body Mass Index less than or equal to 38 kg/m2 but greater than or equal to 19 kg/m2.

6. Baseline evaluation requirements:

   • ≤5% superficial cells on vaginal smear cytology
   • Vaginal pH > 5.0
   • At least one patient self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy (VVA) from the following list that is identified by the subject:
   • Vaginal dryness
   • Vaginal and/or vulvar irritation/itching
   • Dysuria
   • Vaginal pain associated with sexual activity
   • Vaginal bleeding associated with sexual activity (absence vs. presence)

7. All subjects should be judged to be eligible for participation in this study by the principal or sub-investigator physician during a pre-study medical evaluation performed within 28 days of the initial dose of study medication which will include:

   1. a normal or non-clinically significant physical examination, including vital signs
   2. a normal or non-clinically significant pelvic examination that was consistent with hypoestrogenemia
   3. a normal or non-clinically significant breast exam and mammogram
   4. a normal or non-clinically significant ASCUS Papanicolaou ("Pap") smear that is negative for HPV for subjects with an intact uterus and cervix

   5. within normal limits or non-clinically significant laboratory evaluation results (unless otherwise noted in the exclusion criteria) for the following tests:

      • Serum Chemistry
      • Hematology
      • Coagulogram
      • Urinalysis
   6. normal or non-clinically significant 12- Lead ECG.
   7. negative urine drug screen including amphetamine, barbiturates, benzodiazepines, cannabinoid, cocaine, opiates, methadone and phencyclidine with the following exceptions: positive tests for amphetamines, barbiturates, benzodiazepines, or opiates may be allowed provided the subject has a valid prescription and is on a stable regimen that complies with Exclusion Criteria, Section 6.3.2.
   8. negative urine cotinine test.
8. For women with an intact uterus, an endometrial thickness < 5 mm as determined by vaginal ultrasonography.
9. If warranted, other tests or examinations may be performed at the discretion of the Principal Investigator or responsible physician.
10. Ability to use applicator properly.

Exclusion Criteria:

1. Institutionalized subjects will not be used.
2. Any contraindication to estrogen therapy.

3. Social Habits:

   1. Use of any tobacco-containing products within 1 year of the start of the study.
   2. Regular intake of more than 7 units of alcohol per week.
   3. Beginning any new regimens of vitamins or herbal products within 7 days prior to the initial dose of the study medication.
   4. Any recent, significant change in dietary or exercise habits.
   5. History of drug and/or alcohol abuse within one year of start of study.

4. Medications:

   1. Use of any new prescription or over-the-counter (OTC) medication regimens within fourteen (14) days prior to the initial dose of study medication (any necessary medication, unless otherwise noted in the exclusion criteria, for which dosing has been stabilized for a period of at least 14 days prior to initial dosing of study drug and is expected to remain stable for the entire study period is allowed, with the exception of acetaminophen, which may be administered as needed to treat minor adverse events).

   2. Use of hormonal replacement therapies for the following time periods:

      • within 2 weeks of baseline assessment for vaginal therapy (rings, creams, gels)
      • within 4 weeks of baseline assessment for transdermal estrogen alone or estrogen/progestin therapy
      • within 8 weeks of baseline assessment for oral estrogen and/or progestin therapy or intrauterine progestin therapy
      • within 3 months of baseline assessments for progestin implants or estrogen alone injectable therapy
      • within 6 months of baseline assessments for estrogen pellet or progestin injectable therapy
   3. A depot injection or implant of any drug within 3 months prior to administration of study medication.
   4. Currently taking medication indicated for anticoagulation as a result of an excluded condition listed in #5 below. This includes but is not limited to warfarin, heparin, NSAIDs, clopidogrel, dabigatran, etc.

5. Diseases:

   1. History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, urinary, musculoskeletal disease or malignancies unless under medical control and/or deemed not clinically significant by the Principal Investigator or Medical Sub-investigator.
   2. Manifestation or treatment for significant cardiovascular disease (congestive heart failure, stroke or ischemic attack, myocardial infarction, coronary artery bypass, percutaneous angioplasty or > 50% angiographic narrowing of coronary artery, thrombosis of deep veins and arteries, thromboembolic disorders, pulmonary embolism) or history of these conditions.
   3. Coronary artery or cerebrovascular disease.
   4. Current clinically significant liver or kidney dysfunction/disorders.
   5. Current clinically significant gallbladder dysfunction/disorders.
   6. Abnormal or clinically significant breast examination. Acceptable breast examination is defined as no masses or other findings identified that are suspicious of malignancy.
   7. First degree family history of breast cancer.
   8. Current non diet controlled diabetes mellitus or other clinically significant endocrinological disease.
   9. Estrogen-dependent neoplasia
   10. Postmenopausal uterine bleeding
   11. Endometrial hyperplasia
   12. Uncontrolled hypothyroidism
   13. Urinalysis showing an ongoing clinically significant urinary tract infection that requires treatment.
   14. Current clinically significant vaginal infection that requires treatment.
   15. Known chronic lichen sclerosis
   16. Acute illness at the time of either the pre-study medical evaluation or dosing.
   17. History of allergy or hypersensitivity to estradiol, other related products, or any inactive ingredients.
   18. Undiagnosed vaginal bleeding or history of significant risk factors for endometrial cancer.
   19. Increased frequency or severity of headaches while on previous hormone or estrogen therapy.
   20. History of psychiatric disorders occurring within the last 6 months that require hospitalization or medication.
   21. Current hypercalcemia, hypocalcemia, and/or hypertriglyceridemia.
   22. Clinically significant eye/visual abnormalities such as retinal vascular thrombosis, partial or complete loss of vision, proptosis, diplopia, papilledema, retinal vascular lesions.
6. Any reason which, in the opinion of the Principal Investigator or Medical Sub-Investigator, would prevent the subject from safely participating in the study.
7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
8. Sitting blood pressure higher than 150/90 mmHg at screening.
9. Baseline serum estradiol levels >30 pg/mL at screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Estradiol Vaginal Cream; Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.	Drug: Estradiol Vaginal Cream, 0.01%; Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
Active Comparator: Estrace® 0.01% cream; Estrace® 0.01% vaginal cream, administered once daily for 7 days.	Drug: Estrace® 0.01% cream; Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
Placebo Comparator: Placebo Vaginal Cream; Placebo Vaginal Cream, administered once daily for 7 days.	Drug: Placebo Vaginal Cream; Placebo Vaginal Cream ( 1 x 2 g for 7 days)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Endpoint (Vaginal Cytology + Vaginal pH) Equivalence	Treatment comparison of the proportion of patients in the Per Protocol (PP) population who received either Estradiol Vaginal Cream or Estrace® that were identified as responders at the end of the treatment period on Study Day 8. A responder was defined as a patient with at least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology AND vaginal pH ≤ 5.0 with a change from baseline vaginal pH of at least 0.5.	Study Day 8
Primary Endpoint (Vaginal Cytology + Vaginal pH) Comparison of Active Treatments to Placebo	Treatment comparison of the proportion of patients in the Per Protocol (PP) population who received either Estradiol Vaginal Cream, Estrace®, or Placebo that were identified as responders at the end of the treatment period on Study Day 8. A responder was defined as a patient with at least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology AND vaginal pH ≤ 5.0 with a change from baseline vaginal pH of at least 0.5.	Study Day 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the Number of Participants With Treatment Success for the Patient Self-assessment of the Symptoms of Vulvar and Vaginal Atrophy - Equivalence	Evaluation and comparison between Estradiol Vaginal Cream and Estrace® treatment groups of the change from baseline in the most bothersome vulvar and/or vaginal atrophy symptom including vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity, or vaginal bleeding associated with sexual activity as identified by each subject. A score ≤ 1 on Study Day 8 for the most bothersome symptom as identified by the subject at baseline (Study Day -1) was considered a treatment success. A score ≥ 2 on Study Day 8 for the most bothersome symptom as identified by the subject at baseline (Study Day -1) was considered a treatment failure.	Day 8
Comparison of the Number of Participants With Treatment Success for the Patient Self-assessment of the Symptoms of Vulvar and Vaginal Atrophy - Comparison to Placebo	Evaluation and comparison between Estradiol Vaginal Cream, Estrace®, and Placebo treatment groups of the change from baseline in the most bothersome vulvar and/or vaginal atrophy symptom including vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity, or vaginal bleeding associated with sexual activity as identified by each subject. A score ≤ 1 on Study Day 8 for the most bothersome symptom as identified by the subject at baseline (Study Day -1) was considered a treatment success. A score ≥ 2 on Study Day 8 for the most bothersome symptom as identified by the subject at baseline (Study Day -1) was considered a treatment failure.	Day 8

Collaborators and Investigators

• Sponsor: Mylan Pharmaceuticals Inc
• Investigators: Study Chair: Matt Hummel, Ph.D., Mylan Pharmaceuticals Inc; Principal Investigator: Ronald Ackerman, M.D., Comprehensive Clinical Trials, Llc; Principal Investigator: James Andersen, M.D., Meridien Research; Principal Investigator: Keith Aqua, M.D., Visions Clinical Research; Principal Investigator: Theodore Cooper, M.D., Horizons Clinical Research Center, LLC; Principal Investigator: Scott Eder, M.D., Women's Health Research Center/The Center for Women's Health & Wellness, LLC; Principal Investigator: William Koltun, M.D., Medical Center for Clinical Research; Principal Investigator: Gigi Lefebvre, M.D., Meridien Research; Principal Investigator: Leonard Ranasinghe, M.D., Northern CA Research; Principal Investigator: Rovena Reagan, M.D., Women's Health Care Research Corp.; Principal Investigator: Ronald Surowitz, D.O., Health Awareness, Inc.; Principal Investigator: Steven Sussman, M.D., Lawrence OB/GYN Clinical Research, LLC; Principal Investigator: G. Michael Swor, M.D., Physician Care Clinical Research LLC; Principal Investigator: Olga Tudela, M.D., Veritas Research., Corp.; Principal Investigator: Arthur Waldbaum, M.D., Downtown Women's Health Care; Principal Investigator: Maria C Fernandez, M.D., South Coast Research Center, Inc.; Principal Investigator: Gary Carson, M.D, Northern CA Research; Principal Investigator: Lydie Hazan, M.D., Axis Clinical Trials; Principal Investigator: Alfred Moffett, M.D., OB-GYN Associates of Mid Florida; Principal Investigator: Tracey Lemon, M.D., Georgia Center For Women; Principal Investigator: Steven Foley, M.D., MCB Clinical Research Centers, LLC; Principal Investigator: Jason Haffizulla, M.D., Sunrise Medical Research, Inc.; Principal Investigator: Robert Hunter, M.D., ARA-Arizona Research Associates

Study record dates

Study Major Dates

• Study Start: June 1, 2014
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): December 1, 2014

Study Registration Dates

• First Submitted: July 16, 2014
• First Submitted That Met QC Criteria: July 17, 2014
• First Posted (Estimate): July 21, 2014

Study Record Updates

• Last Update Posted (Actual): March 9, 2022
• Last Update Submitted That Met QC Criteria: March 7, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: vaginal dryness; vaginal atrophy; vaginal and/or vulvar irritation/itching; dysuria; vaginal pain and bleeding associated with sexual activity
• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Vaginal Diseases; Vaginitis; Atrophic Vaginitis; Atrophy; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Estrogens; Estradiol
• Other Study ID Numbers: EVCR-11196

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: N/A - Phase I study